ClinicalTrials.gg
CompletedNCT05324683Updated Nov 9, 2026

ILUMIEN-V - AERO: All-comEr Registry of OCT (AERO)

An observational study in Myocardial Ischemia, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Observational

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,684
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Myocardial Ischemia with a site in Germany — 5 open to participants now, 12 under way, none of them phase 3. Myocardial Ischemia · Germany.

Enrollment
3rd of 18
1,684 · median 599
Started
2023
with 1 other
Observational
18 of 62
3 open now
Registered
55th of 62
by date

Among the 62 studies in Myocardial Ischemia with a site in Germany, this one is the 3rd largest by enrollment of the 18 observational ones that give a count, is one of 2 that started in 2023, is one of 18 observational ones, and was the 55th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

5 of the 62 studies in Myocardial Ischemia with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Myocardial Ischemia with a site in Germany, or all of them as a file.
02

Study summary

The study aims to assess contemporary practice in OCT use during routine interven-tional practice and to assess the impact of the MLD-MAX algorithm on real-world PCI in a large unselected European all-comer-study cohort.

Read the detailed description

Angiography is the current standard method to guide PCI strategy in clinical practice. However, angiography has a number of well-described limitations, primarily through only providing an assessment of luminal dimensions without delineation of the burden of atheroma-tous disease. Angiography also provides suboptimal assessment of post PCI complications such as stent underexpansion or malapposi-tion, residual dissections or thrombus, and tissue prolapse. These limi-tations may be overcome in part by intravascular imaging (IVI), which allows tomographic, cross-sectional imaging of the vessel wall. Meta-analyses of randomized and registry studies of IVI-guided vs. angi-ography-guided PCI have suggested that IVI-guidance may improve clinical outcome following PCI.

Optical coherence tomography (OCT) provides high-resolution (10-20 μm) cross-sectional images of plaque microarchitecture, stent place-ment and size and strut coverage. Recently the MLD-MAX algorithm was developed to guide and stand-ardize coronary stent implantation based on sizing of the vessel at the proximal and distal reference using the EEL.

03

Conditions studied

  • Myocardial Ischemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with evidence of myocardial ischemia (e.g. stable angina, silent ischemia, unstable angina, or acute myocardial infarction) un-dergoing OCT-guided lesion evaluation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients with evidence of myocardial ischemia (e.g. stable angi-na, silent ischemia, unstable angina, or acute myocardial infarc-tion) undergoing OCT-guided lesion evaluation (OCT-scan using the devices must be performed either to guide PCI (following the MLD-MAX-algorithm) or to investigate a coronary lesion for fur-ther clinical treatment)
  • Written (defined as legally effective, docu-mented confirmation of a subject's (or their legally authorized representative or guardian) voluntary agreement to participate in a particular clinical study) to participate in this clinical inves-tigation

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,684 participants (actual)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Study population (cohort)

    No study arms; one patient population will be observed.

    Other: No intervention planned

Interventions

  • OtherNo intervention planned

    No intervention planned; study is observational

06

What researchers measure

Primary outcomes

  1. Stent expansion: number of participants with optimal / acceptable / unacceptable stent expansion

    Stent expansion is defined by the MSA achieved in the proximal and distal stented segments relative to their respective reference lumen areas. Stent expansion will be categorised as follows: Optimal stent expansion (y/n); acceptable stent expansion (y/n); unacceptable stent expansion (y/n); post-PCI stent expansion (%).

    Time frame: At baseline

Secondary outcomes

  1. Minimal Stent Area (MSA)

    Imaging Outcome: minimal stent area as continuous measure; Final Post-PCI MSA (per target lesion basis) assessed by final-OCT after PCI; measured at an independent OCT core laboratory. Imaging-Outcome: Minimal-Stent-Area (MSA), continuous measure

    Time frame: At baseline

  2. Mean stent expansion

    The mean stent area (stent volume/analyzed stent length) divided by the average of proximal and distal reference lumen areas x 100

    Time frame: At baseline

  3. Intra-stent plaque protrusion and thrombus: number of major and minor protusion area / stent area

    Defined as a mass attached to the luminal surface or floating within the lumen, meeting the following criteria: Protrusion/thrombus is defined as any intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut, and will be further classified as Major and Minor: * Major: Protrusion area/Stent area at site of tissue protrusion ≥10% and the minimal intra-stent flow area (MSA - protrusion area) is unacceptable (\<90% of respective proximal or distal reference area * Minor: Protrusion area/Stent area at site of tissue protrusion is \<10%, or is ≥10% but the minimal intraluminal flow area (MSA - protrusion area) is acceptable (≥90% of respective proximal or distal reference area

    Time frame: At baseline

  4. Number of participants with untreated reference segmant disease

    Defined as focal disease with untreated MLA \<4.5 mm2 within 5 mm from the proximal and/or distal stent edges. Sub-classified by the amount of untreated lipid plaque, divided into 3 grades: Low (≤90° of lipid arc), Medium (\>90°-\<180° of lipid arc) and High (≥180° of lipid arc).

    Time frame: At baseline

  5. Number of participants with major and minor edge dissections

    Edge dissections will be tabulated as: * Major (%): ≥60 degrees of the circumference of the vessel at site of dissection and ≥3 mm in length * Minor (%): any visible edge dissection \<60 degrees of the cir-cumference of the vessel or \<3 mm in length

    Time frame: At baseline

  6. Number of participants with major and minor stent malapposition

    Defined as frequency (%) of incompletely apposed stent struts (defined as stent struts clearly separated from the vessel wall (lumen bor-der/plaque surface) without any tissue behind the struts with a distance from the adjacent intima of ≥0.2 mm and not associated with any side branch). Malapposition will be further classified as: * Major: if associated with unacceptable stent expansion (as de-fined above) * Minor: if associated with acceptable stent expansion (as defined above) Stent Malapposition will be tabulated as: Major (%); Minor (%); All (Major and Minor) (%)

    Time frame: At baseline

  7. Number of participants with procedural complications

    Defined as prolonged ST-segment elevation or depression (\>30 minutes), cardiac arrest or need for defibrillation or cardioversion or hypotension/heart failure requiring mechanical or intravenous hemody-namic support or intubation or procedural death

    Time frame: At baseline

  8. Number of participants with adverse events

    Target lesion failure (TLF; cardiac death, TV-MI or ischemia-driven target lesion revascularization)

    Time frame: At 30 days follow-up

  9. Number of participants with adverse events

    Target lesion failure (TLF; cardiac death, TV-MI or ischemia-driven target lesion revascularization)

    Time frame: At 6 months follow-up

07

Study locations

1 site
  • Universitätsklinikum Frankfurt - Med. Klinik 3 - Kardiologie
    Frankfurt am Main, 60590, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Mar 2026, 33 months.

Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's 33 months is below that.

Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2026 → Mar 2026 and completion Apr 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 12, 2022
StartActual
May 4, 2023
Primary completionActual
Mar 1, 2026was Apr 2026
CompletionActual
Oct 1, 2026was Apr 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 9, 2026
Primary completion
Apr 2026→Mar 1, 2026 (actual)
Nov 9, 2026
Study completion
Apr 2026→Oct 1, 2026 (actual)
Nov 9, 2026
Enrollment
2000 (estimated)→1684 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Completed
    Primary completion Apr 2026→Mar 1, 2026 (now actual)
    Study completion Apr 2026→Oct 1, 2026 (now actual)
    Enrollment 2000 (estimated)→1684 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05324683
Lead sponsor
IHF GmbH - Institut für Herzinfarktforschung
Collaborators
Abbott
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
May 4, 2023
Primary completion
Mar 1, 2026
Completion
Oct 1, 2026
Last update
Nov 9, 2026

Study contacts

David-Manuel Leistner, Prof Dr med
principal investigator · Universitätsklinikum Frankfurt - Med. Klinik 3 - Kardiologie
Thomas Johnson, Dr med
principal investigator · Bristol Heart Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion